Therapeutic trials in muscular dystrophy. III. Studies of microbial proteinase inhibitors in murine dystrophy.

Abstract

The microbial antiproteinases--antipain, leupeptin, and pepstatin--have been reported to inhibit the degeneration of chicken dystrophic muscle in tissue culture. Trials of antipain and pepstatin, and of leupeptin and pepstatin administered subcutaneously in murine muscular dystrophy, failed to produce evidence of benefit. It is suggested that these antiproteinases cannot pass through an intact sarcolemma into muscle fibers. Further studies with liposomes may allow these agents to enter muscle fibers.

• Authors: A Enomoto, W G Bradley
• Journal: Archives of neurology (Arch Neurol) Vol. 34 Issue 12 Pg. 771-3 (Dec 1977) ISSN: 0003-9942 [Print] United States
• PMID: 337944 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Leupeptins
• Oligopeptides
• Pepstatins
• Protease Inhibitors
• Papain

Topics

• Animals
• Clinical Trials as Topic
• Drug Evaluation, Preclinical
• Drug Therapy, Combination
• Female
• Leupeptins (administration & dosage, therapeutic use)
• Male
• Mice
• Muscular Dystrophy, Animal (drug therapy)
• Oligopeptides (administration & dosage, therapeutic use)
• Papain (antagonists & inhibitors)
• Pepstatins (administration & dosage, therapeutic use)
• Protease Inhibitors